{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '17.2.', 'Inspection of Records', '70', '17.3.', 'Confidentiality and Intellectual Property', '70', '17.4.', 'Retention of Records', '70', '17.5.', 'Financing and Insurance', '71', '18.', 'PUBLICATION POLICY', '71', '19.', 'LIST OF REFERENCES', '72', 'APPENDIX 1. SUBJECT INSTRUCTIONS FOR PROPER USE OF NASAL SPRAY', 'BOTTLE USED IN THE STUDY', '75', 'APPENDIX 2. LIST OF CONTACT DETAILS', '77', 'APPENDIX 3. PEDIATRIC RHINOCONJUNTIVITIS QUALITY OF LIFE', 'QUESTIONNAIRE (PRQLQ)', '78', 'APPENDIX 4. SUMMARY OF CHANGES IN CURRENT PROTOCOL', 'AMENDMENT', '86', 'LIST OF TABLES', 'Table 1:', 'Abbreviations and Specialist Terms', '16', 'Table 2:', 'Schedule of Assessments', '27', 'Table 3:', 'Study Drugs', '37', 'Table 4:', 'Summary of Exclusion of Medication Prior to Screening', '38', 'Table 5:', 'Nasal Symptom Severity Scale', '45', 'Table 6:', 'Non-nasal Symptom Severity Scale', '45', 'Table 7:', 'Grading Criteria for Nasal Examination Findings', '49', 'LIST OF FIGURES', 'Figure 1:', 'Study Design', '29', 'Glenmark', 'CONFIDENTIAL', 'Page 15 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '3.', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', 'The following abbreviations and specialist terms are used in this study protocol.', 'Table 1:', 'Abbreviations and Specialist Terms', 'Abbreviation or Specialist Term', 'Explanation', 'AE', 'adverse event', 'AM', 'Morning', 'AR', 'Allergic rhinitis', 'BID', 'Twice daily', 'CI', 'Confidence interval', 'Cmax', 'Maximum plasma concentration', 'CRF', 'Case report form', 'CRO', 'Contract research organization', 'CSR', 'clinical study report', 'CYP3A4', 'Cytochrome P450 system enzyme 3A4', 'eCRF', 'electronic case report form', 'ENT', 'Ears, nose, and throat', 'FAS', 'Full Analysis Set', 'FDA', 'Food and Drug Administration', 'FDC', 'Fixed dose combination', 'GCP', 'Good Clinical Practice', 'HCI', 'Hydrochloride', 'ICF', 'informed consent form', 'ICH', 'International Conference on Harmonisation', 'IEC', 'independent Ethics Committee', 'IgE', 'Immunoglobulin E', 'IL', 'Interleukin', 'IP', 'Investigational product', 'IRB', 'Institutional Review Board', 'iTNSS', 'Instantaneous Total Nasal Symptom Score', 'iTOSS', 'Instantaneous Total Ocular Symptom Score', 'IVRS', 'Interactive Voice Response System', 'IWRS', 'Interactive Web Response System', 'LAR', 'legally acceptable representative', 'Glenmark', 'CONFIDENTIAL', 'Page 16 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'Abbreviation or Specialist Term', 'Explanation', 'LSM', 'Least squares mean', 'NS', 'Nasal spray', 'OTC', 'Over the counter', 'QD', 'Once daily', 'QOL', 'Quality of Life', 'PM', 'Evening', 'PNSS', 'Physician Assessed Nasal Symptom Score', 'PPS', 'Per Protocol Set', 'PRQLQ', 'Pediatric Rhinoconjunctivitis Quality of Life Questionnaire', 'PT', 'Preferred term', 'rTNSS', 'Reflective Total Nasal Symptom Score', 'rTOSS', 'Reflective Total Ocular Symptom Score', 'RV', 'Randomization visit', 'SAE', 'serious adverse event', 'SAS', 'Safety Analysis Set', 'SAR', 'Seasonal Allergic Rhinitis', 'SAP', 'Statistical Analysis Plan', 'SOC', 'System organ class', 'TEAE', 'Treatment-emergent adverse event', 'TNSS', 'Total Nasal Symptom Score', 'US', 'United States of America', 'USPI', 'United States Prescribing Information', 'Glenmark', 'CONFIDENTIAL', 'Page 17 of 90']\n\n###\n\n", "completion": "END"}